AnalystsArthur HeArthur He's Stock Forecasts
AnalystsArthur He
Sectors:
Industries:
Analyst Ranking
Top 12%
#568 out of 4873 analysts
Average Return
+15.9%
Win Rate
39%29 out of 75
Risk vs Reward
Poor
Good
Arthur He's 5 best and worst ratings
| Name / Ticker | Gain/Loss | Entry Price | Exit Price | Period | Rating |
|---|---|---|---|---|---|
Poseida Therapeutics IncPSTX | +335.27% | $2.16 | $9.38 | 2024-04-21 - 2024-11-26 | Buy |
Poseida Therapeutics IncPSTX | +294.12% | $2.38 | $9.38 | 2024-10-29 - 2024-11-26 | Buy |
Poseida Therapeutics IncPSTX | +269.29% | $2.54 | $9.38 | 2024-10-16 - 2024-11-26 | Buy |
Poseida Therapeutics IncPSTX | +239.86% | $2.76 | $9.38 | 2024-11-14 - 2024-11-26 | Buy |
Poseida Therapeutics IncPSTX | +236.20% | $2.79 | $9.38 | 2024-05-01 - 2024-11-26 | Buy |
Arthur He Analyst Color
Get additional color on Arthur He's coverage of popular stocks
Arthur He's Stock Coverage
| Name / Ticker | No. Ratings | Rating | Price Target | Upside/Downside | Action | Date |
|---|---|---|---|---|---|---|
Vera Therapeutics IncVERA | 1 | Buy | $75.00 | +240.44% | Assumes | 4 days ago |
Adagene IncADAG | 10 | Buy | $8.00 | +400.00% | Reiterates | a month ago |
Adaptimmune Therapeutics PLCADAP | 6 | Buy | $3.00 | +900.00% | Maintains | a month ago |
Lava Therapeutics NvLVTX | 10 | Hold | $1.50 | +18.11% | Reiterates | a month ago |
Prime Medicine IncPRME | 7 | Buy | $10.00 | +657.58% | Reiterates | 2 months ago |
Nektar TherapeuticsNKTR | 3 | Buy | $6.50 | +950.08% | Reiterates | 2 months ago |
Solid Biosciences IncSLDB | 9 | Buy | $20.00 | +622.02% | Maintains | 2 months ago |
Poseida Therapeutics IncPSTX | 17 | Hold | $9.00 | -5.26% | Downgrades | 5 months ago |
Hookipa Pharma IncHOOK | 6 | Buy | $60.00 | +3,981.63% | Maintains | a year ago |
Calliditas Therapeutics AbCALT | 4 | Hold | $39.00 | -2.50% | Downgrades | a year ago |
Bioatla IncBCAB | 6 | Buy | $7.00 | +1,379.92% | Reiterates | a year ago |
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.